NCT00814593View on ClinicalTrials.gov

Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2008

Primary Completion Date

April 30, 2011

Study Completion Date

September 30, 2011

Conditions
Brain and Central Nervous System Tumors
Interventions
BIOLOGICAL

lymphokine-activated killer cells

Instilled into the tumor bed cavity

DRUG

polifeprosan 20 with carmustine implant

Intracranial placement

Trial Locations (1)

92663

Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT00814593 - Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery | Biotech Hunter | Biotech Hunter